{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T16:30:49Z","timestamp":1794241849795,"version":"4.9.0"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertension and organ damage caused by an inappropriate balance between aldosterone and salt are deeply involved in pathologies such as chronic heart failure, chronic kidney disease, and vascular disorders. Mineralocorticoid receptor antagonists are effective not only as antihypertensives, but also as organ-protective drugs, blocking direct aldosterone-induced organ damage independent of blood pressure. In recent years, research into selective aldosterone synthase inhibitors has progressed, resulting in the development of drugs such as baxdrostat, lorundrostat, and vicadrostat. These drugs are highly selective for aldosterone synthase with little inhibition of 11\u03b2-hydroxylase, making them promising antihypertensive and organ-protecting drugs. This article summarizes the basic and clinical research on aldosterone synthase inhibitors to date and reviews their characteristics. Aldosterone synthase inhibitors are drugs with the unprecedented characteristic of reducing blood aldosterone levels. Many studies have shown that low serum aldosterone levels are associated with a reduced risk of cardiovascular events. In fact, clinical trials of aldosterone synthase inhibitors have shown that lowering serum aldosterone levels by 50\u201370% results in lower blood pressure and organ protection. Even a small reduction in serum or local aldosterone levels is highly likely to improve hypertension and organ damage. Clinically, lowering blood aldosterone levels is very important.\u3000Compared to the clinical evidence for mineralocorticoid receptor antagonists, clinical evidence for aldosterone synthase inhibitors remains insufficient. How these two drug types should be used given their differences thus remains unresolved. Discussing the differences in clinical effects in the future is thus important.<\/jats:p>","DOI":"10.1038\/s41440-026-02671-z","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:50:40Z","timestamp":1779331840000},"page":"2190-2200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Aldosterone synthase inhibitors: a new option for antihypertensive, cardio-renal protection"],"prefix":"10.1038","volume":"49","author":[{"given":"Atsuhisa","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2671_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. for the FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329.","journal-title":"N Engl J Med"},{"key":"2671_CR2","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris G, Rossing P, et al. for the FIGARO-DKD Investigators. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"2671_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"2671_CR4","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. for the eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"2671_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldbuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"2671_CR6","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11906-008-0078-y","volume":"10","author":"T Fujita","year":"2008","unstructured":"Fujita T. Aldosterone and CKD in metabolic syndrome. Curr Hypertens Rep. 2008;10:421\u20133.","journal-title":"Curr Hypertens Rep"},{"key":"2671_CR7","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y, et al. Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN). Phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol. 2020;15:1715\u201327.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2671_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41440-022-00940-1","volume":"45","author":"A Sato","year":"2022","unstructured":"Sato A, Nishimoto M. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy. Hypertens Res. 2022;45:1310\u201321.","journal-title":"Hypertens Res"},{"key":"2671_CR9","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1038\/s41440-025-02175-2","volume":"48","author":"A Sato","year":"2025","unstructured":"Sato A, Nishimoto M. Real-world use of finerenone in patients with chronic kidney disease and type 2 diabetes based on large-scale clinical studies: FIDELIO-DKD and FIGARO-DKD. Hypertens Res. 2025;48:1929\u201338.","journal-title":"Hypertens Res"},{"key":"2671_CR10","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med. 1992;120:893\u2013901.","journal-title":"J Lab Clin Med"},{"key":"2671_CR11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3109\/10641969709083193","volume":"19","author":"JW Funder","year":"1997","unstructured":"Funder JW. Aldosterone, salt and cardiac fibrosis. Clin Exp Hypertens. 1997;19:885\u201399.","journal-title":"Clin Exp Hypertens"},{"key":"2671_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/01.HYP.0000203732.03784.3b","volume":"47","author":"JW Funder","year":"2006","unstructured":"Funder JW. Mineralocorticoid receptors and cardiovascular damage: it\u2019s not just aldosterone. Hypertension. 2006;47:634\u20135.","journal-title":"Hypertension"},{"key":"2671_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0021-9681(73)90031-3","volume":"26","author":"PF Sinnett","year":"1973","unstructured":"Sinnett PF, Whyte HM. Epidemiological studies in a total highland population, Tukisenta, New Guinea: Cardiovascular disease and relevant clinical, electrocardiographic, radiological and biochemical findings. J Chron Dis. 1973;26:265\u201390.","journal-title":"J Chron Dis"},{"key":"2671_CR14","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1210\/endo.138.8.5326","volume":"138","author":"CE Gomez-Sanchez","year":"1997","unstructured":"Gomez-Sanchez CE, Zhou MY, Cozza EN, Morita H, Foecking MF, Gomez-Sanchez EP. Aldosterone biosynthesis in the rat brain. Endocrinology. 1997;138:3369\u201373.","journal-title":"Endocrinology"},{"key":"2671_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0006-8993(93)91332-M","volume":"629","author":"SH Mellon","year":"1993","unstructured":"Mellon SH, Deschepper CF. Neurosteroid biosynthesis: Genes for adrenal steroidogenic enzymes are expressed in the brain. Brain Res. 1993;629:283\u201392.","journal-title":"Brain Res"},{"key":"2671_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0303-7207(02)00041-2","volume":"190","author":"L Yu","year":"2002","unstructured":"Yu L, Romero DG, Gomez-Sanchez CE, Gomez-Sanchez EP. Steroidogenic enzyme gene expression in the human brain. Mol Cell Endocrinol. 2002;190:9\u201317.","journal-title":"Mol Cell Endocrinol"},{"key":"2671_CR17","doi-asserted-by":"publisher","first-page":"4796","DOI":"10.1210\/en.2004-0295","volume":"145","author":"EP Gometz-Sanchez","year":"2004","unstructured":"Gometz-Sanchez EP, Ahmad N, Romero D, Gometz-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology. 2004;145:4796\u2013802.","journal-title":"Endocrinology"},{"key":"2671_CR18","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.1016\/S0021-9258(19)30030-4","volume":"264","author":"E Mornet","year":"1989","unstructured":"Mornet E, Dupont J, Vitek A, White PC. Characterization of two genes encoding human steroid 11 beta-hydroxylase (P-450(11) beta). J Biol Chem. 1989;264:20961\u20137.","journal-title":"J Biol Chem"},{"key":"2671_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1073\/pnas.89.4.1458","volume":"89","author":"T Kawamoto","year":"1992","unstructured":"Kawamoto T, Mitsuuchi Y, Toda K, Yokoyama Y, Miyahara K, Miura S, et al. Role of steroid 11beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA. 1992;89:1458\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2671_CR20","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, et al. Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicenter phase III study with a double-blind, randomized withdrawal phase. Lancet Diab Endocrinol. 2020;8:748\u201361. on behalf of the LINC 3 investigators.","journal-title":"Lancet Diab Endocrinol"},{"key":"2671_CR21","doi-asserted-by":"publisher","first-page":"106316","DOI":"10.1016\/j.jsbmb.2023.106316.","volume":"231","author":"J Valentin-Goyco","year":"2023","unstructured":"Valentin-Goyco J, Liu J, Peng HM, Oommen J, Auchus RJ. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450. J Steroid Biochem Mol Biol. 2023;231:106316. https:\/\/doi.org\/10.1016\/j.jsbmb.2023.106316.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2671_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/ijms18051032.","volume":"18","author":"JW Funder","year":"2017","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors \u2013 physiology and pathophysiology. Int J Mol Sci. 2017;18:1032. https:\/\/doi.org\/10.3390\/ijms18051032.","journal-title":"Int J Mol Sci"},{"key":"2671_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Glaser T, Handelin BL, Housman DE, Evans RM. Cloning of human mineralocorticoid receptor complementary DNA; structural and functional kinship with the glucocorticoid receptor. Science. 1987;237:268\u201375.","journal-title":"Science"},{"key":"2671_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev.med.48.1.231","volume":"48","author":"JW Funder","year":"1997","unstructured":"Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med. 1997;48:231\u201340.","journal-title":"Annu Rev Med"},{"key":"2671_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/318635a0","volume":"318","author":"SM Hollenberg","year":"1985","unstructured":"Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985;318:635\u201341.","journal-title":"Nature"},{"key":"2671_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0014-5793(99)01667-1","volume":"464","author":"C Hellal-Levy","year":"1999","unstructured":"Hellal-Levy C, Couette B, Fagart J, Souque A, Gomez-Sanchez C, Rafestin-Oblin ME. Specific hydroxylations determine selective glucocorticoid recognition by human glucocorticoid and mineralocorticoid receptors. FEBS Lett. 1999;464:9\u201313.","journal-title":"FEBS Lett"},{"key":"2671_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1126\/science.2845584","volume":"242","author":"JW Funder","year":"1988","unstructured":"Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target-tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583\u20135.","journal-title":"Science"},{"key":"2671_CR28","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1210\/endo.136.9.7649078","volume":"136","author":"XY Zou","year":"1995","unstructured":"Zou XY, Gomez-Sanchez EP, Cox DL, Coshy D, Gomez-Sanchez CE. Cloning, expression and tissue distribution of the rat NAD+ dependent 11b-hydroxysteroid dehydrogenase. Endocrinology. 1995;136:3729\u201334.","journal-title":"Endocrinology"},{"key":"2671_CR29","doi-asserted-by":"publisher","first-page":"15436","DOI":"10.1074\/jbc.271.26.15436","volume":"271","author":"A Naray-Fejes-Toth","year":"1996","unstructured":"Naray-Fejes-Toth A, Fejes-Toth G. Subcellular localization of the type 2 11beta-hydroxysteroid dehydrogenase. A green fluorescent protein study. L Biol Chem. 1996;271:15436\u201342.","journal-title":"L Biol Chem"},{"key":"2671_CR30","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1210\/endo-127-6-3009","volume":"127","author":"Z Krozowski","year":"1990","unstructured":"Krozowski Z, Stuchberry S, White PC, Monder C, Funder JW. Characterization of 11\u03b2-hydroxysteroid dehydrogenase gene expression: Identification of multiple unique forms of messenger ribonucleic acid in the rat kidney. Endocrinology. 1990;127:3009\u201313.","journal-title":"Endocrinology"},{"key":"2671_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.mce.2011.11.026","volume":"350","author":"JW Funder","year":"2012","unstructured":"Funder JW. Aldosterone and mineralocorticoid receptors: a personal reflection. Mol Cell Endocrinol. 2012;350:146\u201350.","journal-title":"Mol Cell Endocrinol"},{"key":"2671_CR32","first-page":"247","volume":"52","author":"JW Funder","year":"1997","unstructured":"Funder JW, Krozowski Z, Myles K, Sato A, Sheppard KE, Young M. Mineralocorticoid receptors, salt, and hypertension. Recent Prog Horm Res. 1997;52:247\u201362.","journal-title":"Recent Prog Horm Res"},{"key":"2671_CR33","first-page":"E268","volume":"267","author":"K Myles","year":"1994","unstructured":"Myles K, Funder JW. Type 1 (mineralocorticoid) receptors in the guinea-pig. Am J Physiol. 1994;267:E268\u2013272.","journal-title":"Am J Physiol"},{"key":"2671_CR34","first-page":"2263","volume":"80","author":"RC Wilson","year":"1995","unstructured":"Wilson RC, Krozowski ZS, Li K, Obeyesekere V, Razzaghy-Azar M, Harbison MD, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab. 1995;80:2263\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.steroids.2014.08.014","volume":"91","author":"EP Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez EP. Brain mineralocorticoid receptors in cognition and cardiovascular homeostasis. Steroids. 2014;91:20\u201331.","journal-title":"Steroids"},{"key":"2671_CR36","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/j.2040-4603.2014.tb00569.x","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4:965\u201394.","journal-title":"Compr Physiol"},{"key":"2671_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1161\/01.RES.0000080521.15238.E5","volume":"93","author":"W Qin","year":"2003","unstructured":"Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EAG, Goellner JJ, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res. 2003;93:69\u201376.","journal-title":"Circ Res"},{"key":"2671_CR38","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","volume":"110","author":"A Garnier","year":"2004","unstructured":"Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, et al. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation. 2004;110:1819\u201325.","journal-title":"Circulation"},{"key":"2671_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/147323000102900103","volume":"29","author":"A Sato","year":"2001","unstructured":"Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13\u201321.","journal-title":"J Int Med Res"},{"key":"2671_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64\u201368.","journal-title":"Hypertension"},{"key":"2671_CR41","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44\u201349.","journal-title":"Am J Hypertens"},{"key":"2671_CR42","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1038\/hr.2013.74","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A, Fukuda S. Effect of aldosterone breakthrough on albuminuria during treatment with direct renin inhibitor and combined effect with mineralocorticoid receptor antagonist. Hypertens Res. 2013;36:879\u201384.","journal-title":"Hypertens Res"},{"key":"2671_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1291\/hypres.23.25","volume":"23","author":"A Sato","year":"2000","unstructured":"Sato A, Suzuki Y, Shibata H, Saruta T. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients. Hypertens Res. 2000;23:25\u201331.","journal-title":"Hypertens Res"},{"key":"2671_CR44","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/S0895-7061(97)00301-4","volume":"10","author":"J Blacher","year":"1997","unstructured":"Blacher J, Amah G, Girerd X, Kheder A, Ben Mais H, London GM, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subject with essential hypertension. Am J Hypertens. 1997;10:1326\u201334.","journal-title":"Am J Hypertens"},{"key":"2671_CR45","doi-asserted-by":"publisher","first-page":"17A","DOI":"10.1016\/0002-9149(93)90240-D","volume":"71","author":"DA Duprez","year":"1993","unstructured":"Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J, et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993;71:17A\u201320A.","journal-title":"Am J Cardiol"},{"key":"2671_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/sj.jhh.1000590","volume":"12","author":"RH Fagard","year":"1998","unstructured":"Fagard RH, Lijnen PJ, Petrov W. Opposite associations of circulating aldosterone and arterial natriuretic peptide with left ventricular diastolic function in essential hypertension. J Hum Hypertens. 1998;12:195\u2013202.","journal-title":"J Hum Hypertens"},{"key":"2671_CR47","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0002-9149(00)00728-1","volume":"85","author":"MP Sclaich","year":"2000","unstructured":"Sclaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000;85:1199\u2013206.","journal-title":"Am J Cardiol"},{"key":"2671_CR48","doi-asserted-by":"publisher","first-page":"I164","DOI":"10.1161\/01.HYP.23.1_Suppl.I164","volume":"23","author":"M Abe","year":"1994","unstructured":"Abe M, Hamada M, Matsuoka H, Shigematsu Y, Sumimoto T, Hiwada K. Myocardial scintigraphy characteristics in patients with primary aldosteronism. Hypertension. 1994;23:I164\u2013I167. (Suppl I).","journal-title":"Hypertension"},{"key":"2671_CR49","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1177\/108155899904700507","volume":"47","author":"C Napoli","year":"1999","unstructured":"Napoli C, Gregorio F, Leccese M, Abete P, Ambrosio G, Giusti R, et al. Evidence of exercise-induced myocardial ischemia in patients with primary aldosteronism: The Cross-Sectional Primary Aldosteronism and Heart Italian Muticenter Study. J Invest Med. 1999;47:212\u201321.","journal-title":"J Invest Med"},{"key":"2671_CR50","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.CIR.95.6.1471","volume":"95","author":"GP Rossi","year":"1997","unstructured":"Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, et al. Remodeling of the left ventricle in primary aldosteronism due to Conn\u2019s adenoma. Circulation. 1997;95:1471\u20138.","journal-title":"Circulation"},{"key":"2671_CR51","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1161\/01.HYP.27.5.1039","volume":"27","author":"GP Rossi","year":"1996","unstructured":"Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension. 1996;27:1039\u201345.","journal-title":"Hypertension"},{"key":"2671_CR52","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2671_CR53","doi-asserted-by":"publisher","first-page":"5070","DOI":"10.1210\/jc.2005-0681","volume":"90","author":"M Stowasser","year":"2005","unstructured":"Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR54","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1161\/HYPERTENSIONAHA.121.18761","volume":"79","author":"JW Funder","year":"2022","unstructured":"Funder JW, Carey RM. Primary aldosteronism: Where are we now? Where to from here? Hypertension. 2022;79:726\u201335.","journal-title":"Hypertension"},{"key":"2671_CR55","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.jacc.2020.05.071","volume":"76","author":"A Tanaka","year":"2020","unstructured":"Tanaka A, Shibata H, Node K. Suspected borderline aldosteronism in hypertension. The next target? J Am Coll Cardiol. 2020;76:759\u201360.","journal-title":"J Am Coll Cardiol"},{"key":"2671_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjhyper.2005.06.031","volume":"19","author":"M Sartori","year":"2006","unstructured":"Sartori M, Calo LA, Mascagna V. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens. 2006;19:373\u20139.","journal-title":"Am J Hypertens"},{"key":"2671_CR57","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/ajh.2011.245","volume":"25","author":"H Shibata","year":"2012","unstructured":"Shibata H, Itoh H. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension. Am J Hypertens. 2012;25:514\u201323.","journal-title":"Am J Hypertens"},{"key":"2671_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1037\/0735-7044.106.1.62","volume":"106","author":"MS Oitzl","year":"1992","unstructured":"Oitzl MS, de Kloet ER. Selective corticosteroidantagonists modulate specific aspects of spatial orientation learning. Behav Neurosci. 1992;106:62\u201371.","journal-title":"Behav Neurosci"},{"key":"2671_CR59","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1460-9568.1994.tb00319.x","volume":"6","author":"C Sandi","year":"1994","unstructured":"Sandi C, Rose SPR. Corticosteroid receptor antagonists are amnesic for passive avoidance learning in day-old chicks. Eur J Neurosci. 1994;6:1292\u20137.","journal-title":"Eur J Neurosci"},{"key":"2671_CR60","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/S0306-4530(03)00103-3","volume":"29","author":"MY Tytherleigh","year":"2004","unstructured":"Tytherleigh MY, Vedhara K, Lightman SL. Mineralocorticoid and glucocorticoid receptor and their differential effects on memory. Psychoneuroendocrinology. 2004;29:712\u201323.","journal-title":"Psychoneuroendocrinology"},{"key":"2671_CR61","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/S0735-1097(02)02382-3","volume":"40","author":"MF Rousseau","year":"2002","unstructured":"Rousseau MF, Gurne O, Duprez D, van Mieghem W, Robert A, Ahn S, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy. J Am Coll Cardiol. 2002;40:1596\u2013601. Belgian RALES investigators.","journal-title":"J Am Coll Cardiol"},{"key":"2671_CR62","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/00041552-200103000-00011","volume":"10","author":"JW Funder","year":"2001","unstructured":"Funder JW. Non-genomic actions of aldosterone: role in hypertension. Curr Opin Nephrol Hypertens. 2001;10:227\u201330.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2671_CR63","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1210\/endo.138.8.5352","volume":"138","author":"A Sato","year":"1997","unstructured":"Sato A, Liu JP, Funder JW. Aldosterone rapidly represses protein kinase C activity in neonatal rat cardiomyocytes in vitro. Endocrinology. 1997;138:3410\u20136.","journal-title":"Endocrinology"},{"key":"2671_CR64","doi-asserted-by":"publisher","first-page":"3F","DOI":"10.1016\/S0002-9149(02)02418-9","volume":"90","author":"ME Mendelsohn","year":"2002","unstructured":"Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol. 2002;90:3F\u20136F.","journal-title":"Am J Cardiol"},{"key":"2671_CR65","doi-asserted-by":"publisher","first-page":"C1178","DOI":"10.1152\/ajpcell.00185.2009","volume":"297","author":"Q Ding","year":"2009","unstructured":"Ding Q, Gros R, Limbird LE, Chorazyczewski J, Feldman RD. Estradiol-mediated ERK phosphorylation and apoptosis in vascular smooth muscle cells requires GPR 30. Am J Physiol Cell Physiol. 2009;297:C1178\u2013C1187.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2671_CR66","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1161\/HYPERTENSIONAHA.110.161653","volume":"57","author":"R Gros","year":"2011","unstructured":"Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterbum JB, Chorazyczewski J, et al. GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension. 2011;57:442\u201351.","journal-title":"Hypertension"},{"key":"2671_CR67","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1210\/me.2004-0469","volume":"19","author":"C Grossman","year":"2005","unstructured":"Grossman C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, et al. Human mineralocorticoid receptor expression renders cell responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19:1697\u2013710.","journal-title":"Mol Endocrinol"},{"key":"2671_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1210\/er.2005-0004","volume":"26","author":"JW Funder","year":"2005","unstructured":"Funder JW. The nongenomic actions of aldosterone. Endocr Rev. 2005;26:313\u201321.","journal-title":"Endocr Rev"},{"key":"2671_CR69","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1161\/HYPERTENSIONAHA.116.07716","volume":"69","author":"K Bogman","year":"2017","unstructured":"Bogman K, Schwab D, Delporte ML, Palermo G, Amrein K, Mohr S, et al. Preclinical and early clinical profile of a highly selective and potent oral inhibitor of aldosterone synthase (CYP11B2). Hypertension. 2017;69:189\u201396.","journal-title":"Hypertension"},{"key":"2671_CR70","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1210\/clinem\/dgae823","volume":"110","author":"M Azizi","year":"2025","unstructured":"Azizi M, Riancho J, Amar L. Aldosterone synthase inhibitors: A revival for treatment of renal and cardiovascular diseases. J Clin Endocrinol Metab. 2025;110:e557\u2013565.","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR71","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41440-022-01070-4","volume":"46","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Bond M, Murphy B, Hui J, Isaacsohn J. Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers. Hypertens Res. 2023;46:108\u201318.","journal-title":"Hypertens Res"},{"key":"2671_CR72","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/cpdd.1371","volume":"13","author":"MW Freeman","year":"2024","unstructured":"Freeman MW, Halvorsen YD, Bond M, Murphy B, Isaacsohn J. Results from a phase 1 study assessing the pharmacokinetics of the aldosterone synthase inhibitor baxdrostat in participants with varying degrees of renal function. Clin Pharm Drug Dev. 2024;13:410\u20138.","journal-title":"Clin Pharm Drug Dev"},{"key":"2671_CR73","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. for the BrigHTN investigators. Phase 2 trial in patients with resistant hypertension demonstrated that baxdrostat is effective in improving BP levels. N Engl J Med. 2023;388:395\u2013405.","journal-title":"N Engl J Med"},{"key":"2671_CR74","doi-asserted-by":"publisher","first-page":"e638","DOI":"10.1210\/clinem\/dgad071","volume":"108","author":"CE Gomez-Sanchez","year":"2023","unstructured":"Gomez-Sanchez CE, Gomez-Sanchez EP. Aldosterone synthase inhibitors and the treatment of essential hypertension. J Clin Endocrinol Metab. 2023;108:e638\u2013639.","journal-title":"J Clin Endocrinol Metab"},{"key":"2671_CR75","first-page":"1363","volume":"393","author":"JM Flack","year":"2025","unstructured":"Flack JM, Azizi M, Brown JM, Dwyer JP, Fronczek J, Jones ES, et al. for BaxHTN investigators. Effic Saf baxdrostat uncontrolled resistant hypertension N Engl J Med. 2025;393:1363\u201374.","journal-title":"Effic Saf baxdrostat uncontrolled resistant hypertension N Engl J Med"},{"key":"2671_CR76","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1056\/NEJMc2508629","volume":"393","author":"AF Turcu","year":"2025","unstructured":"Turcu AF, Freeman MW, Bancos I, Ben-Shlomo A, Hamidi O, Hamrahian AH, et al. Phase 2a study of baxdrostat in primary aldosteronism. N Engl J Med. 2025;393:515\u20138. for the SPARK investigator group.","journal-title":"N Engl J Med"},{"key":"2671_CR77","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1001\/jama.2023.16029","volume":"330","author":"LJ Laffin","year":"2023","unstructured":"Laffin LJ, Rodman D, Luther JM, Vaidya A, Weir MR, Rajicic N, et al. for the Target-HTN investigator. Aldosterone synthase inhibition with lorundrostat for uncontrolled hypertension. The Target-HTN randomized clinical trial. JAMA. 2023;330:1140\u201350.","journal-title":"JAMA"},{"key":"2671_CR78","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1001\/jama.2025.9413","volume":"334","author":"M Saxena","year":"2025","unstructured":"Saxena M, Laffin L, Borghi C, Fernandez BF, Ghali J, Kopjar B, et al. for the Launch-HTN investigators. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension. The Launch-HTN randomized clinical trial. JAMA. 2025;334:409\u201318.","journal-title":"JAMA"},{"key":"2671_CR79","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2501440","volume":"392","author":"LJ Laffin","year":"2025","unstructured":"Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, et al. for the Advance-HTN investigators. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392:1813\u201323.","journal-title":"N Engl J Med"},{"key":"2671_CR80","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske S, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomized, controlled, phase 2 trial. Lancet. 2024;403:379\u201390. on behalf of the Asi in CKD group.","journal-title":"Lancet"},{"key":"2671_CR81","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/ndt\/gfae263","volume":"40","author":"PK Judge","year":"2025","unstructured":"Judge PK, Tuttle KR, Staplin N, Hauske SJ, Zhu D, Sardell R, et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI690517): a rational for the EASi-KIDNEY trial. Nephrol Dial Transpl. 2025;40:1175\u201386.","journal-title":"Nephrol Dial Transpl"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02671-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02671-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:05:47Z","timestamp":1783296347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02671-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2671"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02671-z","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}